Moderna (MRNA) Stock Soars 13% on In Vivo CAR-T Breakthrough and Flu Vaccine Progress

Moderna's stock jumped 13% following two significant clinical developments: the unveiling of an in vivo CAR-T immunotherapy program targeting autoimmune diseases and a unanimous 9-0 FDA panel vote supporting its mRNA-based flu vaccine candidate. These milestones demonstrate the company's pipeline expansion beyond COVID-19 and validate its mRNA platform's versatility across therapeutic areas.

Moderna's dual catalysts reflect the biotech company's strategic pivot toward sustainable growth beyond pandemic revenues. The CAR-T breakthrough signals expansion into the immuno-oncology and autoimmune space, a multi-billion-dollar market where competitors like Gilead and Juno Therapeutics have already established footholds. In vivo CAR-T therapies represent a next-generation approach, potentially offering improved safety and manufacturability compared to ex vivo approaches that dominate current approvals. The unanimous FDA panel recommendation for its flu vaccine strengthens Moderna's position in preventive medicine and diversifies its commercial portfolio.

These developments arrive as investors scrutinize Moderna's long-term viability amid declining COVID vaccine demand. The company's mRNA platform has proven technically sound across multiple indications, yet market skeptics questioned whether initial pandemic success could translate to sustainable commercial products. Positive regulatory signals validate management's R&D investments and suggest the platform extends beyond infectious disease applications.

For shareholders, these announcements reduce single-product risk and support higher valuation multiples if approvals materialize. The flu vaccine could capture meaningful market share given rising demand for mRNA-based seasonal immunizations. The CAR-T program, if successful, enters an established but competitive therapeutic category.

Investors should monitor Phase 3 efficacy data for the flu vaccine and clinical readouts from the CAR-T program. Competitive dynamics with Pfizer's similar initiatives and regulatory timelines will determine whether Moderna can achieve commercial scale beyond COVID. The stock's reaction also underscores renewed confidence in mRNA platform durability.

• →Moderna revealed an in vivo CAR-T program for autoimmune diseases, expanding beyond its COVID vaccine focus.
• →The company secured a unanimous 9-0 FDA panel vote supporting its mRNA flu vaccine candidate.
• →These developments reduce investor concerns about post-pandemic revenue sustainability.
• →CAR-T and flu vaccines address large markets with meaningful commercial potential if approved.
• →Upcoming clinical data and regulatory decisions will determine whether momentum continues.